If you are looking into stocks that have made massive gains this year so far, then it is difficult to look beyond the Infinity Pharmaceuticals (NASDAQ: INFI) stock.
The Infinity stock has been on a strong rally in 2021 and so far it has recorded gains of as big as 80%. Earlier this month, the biotech stock received a major boost after it released data from the Phase 2 clinical trial of one of its products. Following the announcement on February 11, Infinity has been in focus among many investors.
The clinical trial looked into the efficacy and safety of a combination of Infinity’s eganelisib with Bristol Myers Squibb’s nivolumab. The combination is meant for treating patients who might be suffering from advanced urothelial cancer. As per the data, the combination displayed a rise in immune activation and a drop in immune suppression. It is a significant development for Infinity and the rally in the stock in recent days is understandable. Investors could consider tracking the stock this week.